| Primary |
| Depression |
33.3% |
| Atrial Fibrillation |
16.7% |
| Cardiac Disorder |
16.7% |
| Dyslipidaemia |
16.7% |
| Pulmonary Embolism |
16.7% |
|
|
| Secondary |
| Product Used For Unknown Indication |
28.9% |
| Drug Use For Unknown Indication |
22.5% |
| Depression |
8.4% |
| Bipolar I Disorder |
7.2% |
| Anxiety |
5.4% |
| Psychotic Disorder |
4.8% |
| Parkinson's Disease |
3.6% |
| Hypertension |
3.0% |
| Insomnia |
2.5% |
| Drug Exposure During Pregnancy |
1.8% |
| Agitation |
1.7% |
| Dementia Alzheimer's Type |
1.5% |
| Cardiovascular Disorder |
1.3% |
| Pain |
1.3% |
| Schizophrenia |
1.2% |
| Suicide Attempt |
1.1% |
| Diabetes Mellitus |
1.0% |
| Major Depression |
1.0% |
| Prophylaxis |
1.0% |
| Abnormal Behaviour |
0.9% |
|
| Somnolence |
13.2% |
| Completed Suicide |
7.2% |
| Pulmonary Embolism |
7.2% |
| Suicide Attempt |
7.2% |
| Thrombocytopenia |
7.2% |
| Renal Failure Acute |
5.4% |
| Tremor |
5.4% |
| Premature Baby |
4.8% |
| Rhabdomyolysis |
4.8% |
| Status Epilepticus |
4.2% |
| Disseminated Intravascular Coagulation |
3.6% |
| Off Label Use |
3.6% |
| Oropharyngeal Spasm |
3.6% |
| Renal Failure |
3.6% |
| Toxic Skin Eruption |
3.6% |
| Withdrawal Syndrome |
3.6% |
| Cytolytic Hepatitis |
3.0% |
| Intra-uterine Death |
3.0% |
| Overdose |
3.0% |
| Posterior Reversible Encephalopathy Syndrome |
3.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.3% |
| Drug Use For Unknown Indication |
22.7% |
| Depression |
9.8% |
| Anxiety |
5.7% |
| Hypertension |
4.5% |
| Hiv Infection |
3.9% |
| Prophylaxis |
2.6% |
| Schizophrenia |
2.6% |
| Pain |
2.3% |
| Hepatitis C |
2.2% |
| Epilepsy |
1.9% |
| Atrial Fibrillation |
1.8% |
| Acute Lymphocytic Leukaemia |
1.8% |
| Insomnia |
1.8% |
| Bipolar Disorder |
1.6% |
| Agitation |
1.5% |
| Psychotic Disorder |
1.4% |
| Type 2 Diabetes Mellitus |
1.3% |
| Thrombosis Prophylaxis |
1.2% |
| Bipolar I Disorder |
1.0% |
|
| Thrombocytopenia |
8.3% |
| Vomiting |
8.3% |
| Weight Decreased |
8.3% |
| Hyponatraemia |
6.8% |
| Renal Failure Acute |
6.2% |
| Hepatocellular Injury |
5.8% |
| Toxic Skin Eruption |
5.2% |
| Neutropenia |
4.9% |
| Pulmonary Embolism |
4.9% |
| Renal Failure |
4.9% |
| Pyrexia |
4.6% |
| Suicide Attempt |
4.6% |
| Urinary Tract Infection |
4.3% |
| Somnolence |
4.0% |
| International Normalised Ratio Increased |
3.7% |
| Tachycardia |
3.4% |
| Stevens-johnson Syndrome |
3.1% |
| Urinary Retention |
3.1% |
| Withdrawal Syndrome |
3.1% |
| Bacterial Sepsis |
2.5% |
|
| Interacting |
| Drug Use For Unknown Indication |
41.9% |
| Insomnia |
11.1% |
| Agitation |
10.3% |
| Product Used For Unknown Indication |
8.5% |
| Pain |
5.1% |
| Depression |
4.3% |
| Avoidant Personality Disorder |
3.4% |
| Hepatitis C |
2.6% |
| Tuberculosis |
2.6% |
| Anxiety Disorder |
1.7% |
| Asthma |
1.7% |
| Hiv Infection |
1.7% |
| Type 2 Diabetes Mellitus |
1.7% |
| Anxiety |
0.9% |
| Arteritis |
0.9% |
| Delirium Tremens |
0.9% |
| Haemoglobin Decreased |
0.9% |
|
| Insomnia |
20.0% |
| Sleep Disorder |
20.0% |
| Therapeutic Product Ineffective |
10.0% |
| Withdrawal Syndrome |
10.0% |
| Drug Interaction |
5.0% |
| Fall |
5.0% |
| International Normalised Ratio Increased |
5.0% |
| Musculoskeletal Pain |
5.0% |
| Myalgia |
5.0% |
| Psychomotor Retardation |
5.0% |
| Somnolence |
5.0% |
| Weight Decreased |
5.0% |
|
